Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a second pill stop your migraine? new study investigates

NCT ID NCT07609914

Symptom relief Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 25, 2026 · Updated 8 times

Summary

This study looks at whether taking a second dose of the migraine medication rimegepant is safe and helpful for adults whose migraine pain isn't fully relieved by the first dose. About 400 people aged 18 and older with a history of migraines will take part. Researchers will track side effects and how satisfied participants are with their pain relief.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion: * Eligible participants include adult participants aged 18 years of age or older with a minimum 1-year history of migraine (with or without aura) consistent with International Classification of Headache Disorders, 3rd Edition * Eligible participants must be currently using acute migraine treatment in accordance with the local label and have all of the following on average across the 12 weeks prior to the Screening Visit and, during the first 28 days of the observation phase (OP): (1) 6-14 monthly migraine days (MMDs); (2) \<15 monthly headache days (MHDs) (migraine or non-migraine); and (3) \<7 monthly non-migraine headache days. Exclusion: * Participants with headaches occurring ≥15 days per month (migraine or non-migraine) on average across the 12 weeks prior to the Screening Visit and ≥7 non-migraine headache days per month on average across the 12 weeks prior to the Screening Visit would not be eligible.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute treatment of migraine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute treatment of migraine

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    14 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Brainstorm Research

    RECRUITING

    Miami, Florida, 33176, United States

  • Clinical Neuroscience Solutions

    RECRUITING

    Orlando, Florida, 32801, United States

  • Clinical Research Institute

    RECRUITING

    Los Angeles, California, 90048, United States

  • FutureSearch Trials of Dallas

    RECRUITING

    Dallas, Texas, 75251, United States

  • FutureSearch Trials of Neurology

    RECRUITING

    Austin, Texas, 78731, United States

  • Headache Wellness Center

    RECRUITING

    Greensboro, North Carolina, 27405, United States

  • Hope Clinical Research

    RECRUITING

    Canoga Park, California, 91303, United States

  • Medstar Health - Department of Neurology

    NOT_YET_RECRUITING

    McLean, Virginia, 22101, United States

  • Michigan Headache & Neurological Institute

    RECRUITING

    Ann Arbor, Michigan, 48104, United States

  • Neurology Offices of South Florida

    RECRUITING

    Boca Raton, Florida, 33428, United States

  • New England Regional Headache Center

    RECRUITING

    Worcester, Massachusetts, 01609, United States

  • Proven Endpoints, LLC

    RECRUITING

    Ridgeland, Mississippi, 39157, United States

  • Shaare Zedek Medical Center

    NOT_YET_RECRUITING

    Jerusalem, Jerusalem, 9103102, Israel

  • Sourasky Medical Center

    NOT_YET_RECRUITING

    Tel Aviv, 6423906, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.